13 June 2018
Myomo, Inc., a medical device company specializing in orthotics, is hoping to become the first Regulation A+ issuer to be listed on the New York Stock Exchange’s small-cap market (NYSE MKT). In its offering statement for a Regulation A+ offering, which has been qualified by the SEC, Myomo disclosed its intent to apply to list its common stock on the NYSE MKT.
Before Myomo may commence trading on the NYSE MKT, the offering must be completed, Myomo must file a post-qualification amendment to the offering statement and Form 8-A registration statement, and the SEC must qualify such post-qualification amendment.
For more information, see here.